Skip to main content

Published locations for Atezolizumab (Tecentriq) bladder cancer indication withdrawn in United States

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Atezolizumab (Tecentriq) bladder cancer indication withdrawn in United States

User login

  • Reset your password
  • /content/atezolizumab-tecentriq-bladder-cancer-indication-withdrawn-united-states
  • /fedprac/article/259868/genitourinary-cancer/atezolizumab-tecentriq-bladder-cancer-indication
  • /internalmedicinenews/article/259868/genitourinary-cancer/atezolizumab-tecentriq-bladder-cancer
  • /oncologypractice/article/259868/genitourinary-cancer/atezolizumab-tecentriq-bladder-cancer
  • /fedprac/avaho/article/259868/genitourinary-cancer/atezolizumab-tecentriq-bladder-cancer-indication
  • /hematology-oncology/article/259868/genitourinary-cancer/atezolizumab-tecentriq-bladder-cancer
  • /internalmedicine/article/259868/genitourinary-cancer/atezolizumab-tecentriq-bladder-cancer